ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model...

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetic nephropathy is a leading cause of end-stage renal disease, driven by the global rise in type 2 diabetes.
• Novel therapeutic strategies are essential to combat the increasing prevalence of this condition.
• ONO-1301, a prostacyclin analog, inhibits thromboxane A2 synthase and is formulated for sustained release.

Purpose of the Study:

• To investigate the therapeutic potential of intermittent slow-release ONO-1301 (SR-ONO) in a mouse model of type 2 diabetic nephropathy.
• To evaluate the direct effects of ONO-1301 on mesangial cells under high glucose conditions.

Main Methods:

• Obese type 2 diabetic mice (db/db) received subcutaneous injections of SR-ONO (3mg/kg) every 3 weeks.
• Biomarkers of kidney damage, including albuminuria, glomerular hypertrophy, collagen accumulation, and inflammatory cell infiltration, were assessed.
• ONO-1301's effects on high glucose-induced changes in cultured mouse mesangial cells were examined.

Main Results:

• SR-ONO treatment significantly reduced albuminuria, glomerular hypertrophy, type IV collagen deposition, and monocyte/macrophage infiltration in diabetic mice.
• Levels of TGF-β1, α-smooth muscle actin (α-SMA), and MCP-1 were decreased by SR-ONO administration.
• In vitro, ONO-1301 suppressed high glucose-induced increases in TGF-β, type IV collagen, α-SMA, MCP-1, and fibronectin in mesangial cells, mediated partly by prostacyclin (PGI2) receptor signaling.

Conclusions:

• Intermittent administration of SR-ONO demonstrates therapeutic efficacy against type 2 diabetic nephropathy in a preclinical model.
• SR-ONO may exert protective effects on mesangial cells, offering a potential new treatment avenue for diabetic kidney disease.